

SEARCH REQUEST FORM

Scientific and Technical Information Center

RECEIVED

Access DB#

76864

SEP 27 2002

STIC

Requester's Full Name: Jeffrey E. Russel Examiner #: 62785 Date: 9-27-2002
 Art Unit: 1653 Phone Number 308-3975 Serial Number: 091781133
 Mail Box and Bldg/Room Location: CMI-9801 / CMI-9807 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.


Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Methods Of Enhancing The Bioavailability Of A Drug

Inventors (please provide full names): N. Hayward, M. Getter


Earliest Priority Filing Date: 2-9-2001

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



If there are many hits, please require R to be alkyl.

keywords are amyloid, P-glycoprotein, brain.

Thank you.


Edward Hart
 Technical Info. Specialist
 STIC/Biotech
 CMI 6B02 Tel: 305-9203

STAFF USE ONLY

Type of Search

Vendors and cost where applicable

Searcher: _____	NA Sequence (#) _____	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: <u>10/30/02</u>	Bibliographic _____	Dr. Link _____
Date Completed: <u>10/1/02</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: <u>20</u>	Fulltext _____	Sequence Systems _____
Clerical Prep Time: <u>21</u>	Patent Family _____	WWW/Internet _____
Online Time: <u>21</u>	Other _____	Other (specify) _____

=> file hcaplus
 FILE 'HCAPLUS' ENTERED AT 14:52:23 ON 01 OCT 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 1 Oct 2002 VOL 137 ISS 14
 FILE LAST UPDATED: 30 Sep 2002 (20020930/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d stat que
 L4

STR




NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE

L6 406 SEA FILE=REGISTRY SSS FUL L4
 L9 1207 SEA FILE=REGISTRY ABB=ON PLU=ON AMYLOID/BI
 L11 668914 SEA FILE=HCAPLUS ABB=ON PLU=ON 18
 L12 3258 SEA FILE=HCAPLUS ABB=ON PLU=ON L9
 L13 16312 SEA FILE=HCAPLUS ABB=ON PLU=ON L12 OR ?AMYLOID?
 L14 6436 SEA FILE=HCAPLUS ABB=ON PLU=ON L*** OR P (W) GLYCOPROTEIN
 L18 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L13 AND L11 AND L14
 L19 STR



VAR G1=ME/ET/I-PR/N-PR/I-BU/N-BU/S-BU/T-BU
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE

L20 6 SEA FILE=REGISTRY SUB=L6 SSS FUL L19
 L21 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L20
 L22 5 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 OR L21

=> d ibib abs hitrn l22 tot

L22 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:618207 HCAPLUS

DOCUMENT NUMBER: 135:190398

TITLE: Nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers

INVENTOR(S): Roth, Frederick P.; Van Huffel, Christophe; White, James V.; Shyjan, Andrew W.

PATENT ASSIGNEE(S): Millennium Predictive Medicine, Inc., USA

SOURCE: PCT Int. Appl., 126 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001061048	A2	20010823	WO 2001-US5263	20010216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002051978	A1	20020502	US 2001-788100	20010216
PRIORITY APPLN. INFO.:			US 2000-183312P	P 20000217
AB The present invention is directed to the identification of markers that can be used to det. the sensitivity of cancer cells to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. Nucleic acid arrays were used to det. the level of expression of sequences (genes) found in 60 different solid tumor cancer cell lines selected from the NCI 60 cancer cell line series. Expression anal. was used to identify markers assocd. with sensitivity to certain chemotherapeutic agents.				
IT 117871-30-4 126236-73-5 , Glycophosphoprotein P (human clone pSVB1/pSVM113/pSVC6/pSVA4/pSVS13/pSVTH21 gene mdrl protein moiety reduced) 154947-97-4 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (amino acid sequence; nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)				
IT 148784-57-0 , GenBank X68830 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses) (nucleotide sequence; nucleic acid markers useful for the identification, assessment, prevention and therapy of human cancers)				
L22 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2002 ACS				
ACCESSION NUMBER: 2001:597818 HCAPLUS				
DOCUMENT NUMBER: 135:185457				
TITLE: Methods for enhancing the bioavailability of a drug				
INVENTOR(S): Hayward, Neil J.; Gefter, Malcolm L.				
PATENT ASSIGNEE(S): Praecis Pharmaceuticals Inc., USA				
SOURCE: PCT Int. Appl., 86 pp.				
CODEN: PIXXD2				
DOCUMENT TYPE: Patent				
LANGUAGE: English				
FAMILY ACC. NUM. COUNT: 1				
PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058470	A2	20010816	WO 2001-US4178	20010209
WO 2001058470	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
 ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-181833P P 20000211
 US 2000-181943P P 20000211

AB The invention provides methods and compns. for enhancing the
 bioavailability of a drug in a subject. The present invention also
 provides methods and compns. for treating or preventing hepatic injury in
 humans. The invention further provides methods for identifying
 hydrophobic peptides, e.g., .beta.-amyloid peptide derivs., which are
 useful in enhancing bioavailability of a drug. Thus, brain levels of
 PPI-58 were elevated in the presence of cyclosporin A. The
 biodistribution data demonstrated that higher levels were obsd. within the
 small intestine in the presence of cyclosporin A.

IT 290828-24-9 290828-45-4
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU
 (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (methods for enhancing drug bioavailability)

L22 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 2000:628174 HCAPLUS
 DOCUMENT NUMBER: 133:221242
 TITLE: Modulators of beta-amyloid peptide aggregation
 comprising D-amino acids
 INVENTOR(S): Findeis, Mark A.; Phillips, Kathryn; Olson, Gary L.;
 Self, Christopher
 PATENT ASSIGNEE(S): Praecis Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052048	A1	20000908	WO 2000-US5574	20000303
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1161449	A1	20011212	EP 2000-916028	20000303
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000008738	A	20011226	BR 2000-8738	20000303
PRIORITY APPLN. INFO.:			US 1999-122736P P 19990304	
			WO 2000-US5574 W 20000303	

AB Compds. that modulate natural .beta. amyloid peptide aggregation are
 provided. The modulators of the invention comprise a peptide, preferably
 based on a .beta. amyloid peptide, that is comprised entirely of D-amino

acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a .beta. amyloid peptide, preferably a retro-inverso isomer of A.beta.17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an acetate group, an alkyl amide group, an aryl amide group or a hydroxy group. Pharmaceutical compns. comprising the compds. of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compds. of the invention, are also disclosed.

IT 290828-24-9 290828-30-7 290828-31-8
290828-45-4 290828-62-5 290828-63-6

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(modulators of .beta.-amyloid peptide aggregation comprising D-amino acids)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:795994 HCAPLUS

DOCUMENT NUMBER: 132:31744

TITLE: Gene probes used for genetic profiling in healthcare screening and planning

INVENTOR(S): Roberts, Gareth Wyn

PATENT ASSIGNEE(S): Genostic Pharma Ltd., UK

SOURCE: PCT Int. Appl., 745 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964627	A2	19991216	WO 1999-GB1780	19990604
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			GB 1998-12099	A 19980606
			GB 1998-13291	A 19980620
			GB 1998-13611	A 19980624
			GB 1998-13835	A 19980627
			GB 1998-14110	A 19980701
			GB 1998-14580	A 19980707
			GB 1998-15438	A 19980716
			GB 1998-15574	A 19980718
			GB 1998-15576	A 19980718
			GB 1998-16085	A 19980724
			GB 1998-16086	A 19980724
			GB 1998-16921	A 19980805

GB 1998-17097 A 19980807
 GB 1998-17200 A 19980808
 GB 1998-17632 A 19980814
 GB 1998-17943 A 19980819

AB There is considerable evidence that significant factor underlying the individual variability in response to disease, therapy and prognosis lies in a person's genetic make-up. There have been numerous examples relating that polymorphisms within a given gene can alter the functionality of the protein encoded by that gene thus leading to a variable physiol. response. In order to bring about the integration of genomics into medical practice and enable design and building of a technol. platform which will enable the everyday practice of mol. medicine a way must be invented for the DNA sequence data to be aligned with the identification of genes central to the induction, development, progression and outcome of disease or physiol. states of interest. According to the invention, the no. of genes and their configurations (mutations and polymorphisms) needed to be identified in order to provide crit. clin. information concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome. The identification of the identity of the core group of genes enables the invention of a design for genetic profiling technologies which comprises of the identification of the core group of genes and their sequence variants required to provide a broad base of clin. prognostic information - "genostics". The "Genostic" profiling of patients and persons will radically enhance the ability of clinicians, healthcare professionals and other parties to plan and manage healthcare provision and the targeting of appropriate healthcare resources to those deemed most in need. The use of this invention could also lead to a host of new applications for such profiling technologies, such as identification of persons with particular work or environment related risk, selection of applicants for employment, training or specific opportunities or for the enhancing of the planning and organization of health services, education services and social services.

IT 106602-62-4, Amylin 148125-60-4
 RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (core group of disease-related genes; gene probes used for genetic profiling in healthcare screening and planning)

IT 158736-49-3, .beta.-Secretase
 RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (.alpha. and .beta. and .gamma., core group of disease-related genes; gene probes used for genetic profiling in healthcare screening and planning)

L22 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1999:795993 HCAPLUS
 DOCUMENT NUMBER: 132:31743
 TITLE: Gene probes used for genetic profiling in healthcare screening and planning
 INVENTOR(S): Roberts, Gareth Wyn
 PATENT ASSIGNEE(S): Genostic Pharma Limited, UK
 SOURCE: PCT Int. Appl., 149 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9964626 A2 19991216 WO 1999-GB1779 19990604
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9941586 A1 19991230 AU 1999-41586 19990604
AU 9941587 A1 19991230 AU 1999-41587 19990604
GB 2339200 A1 20000119 GB 1999-12914 19990604
GB 2339200 B2 20010912
EP 1084273 A1 20010321 EP 1999-925207 19990604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
PRIORITY APPLN. INFO.: GB 1998-12098 A 19980606
 GB 1998-28289 A 19981223
 GB 1998-16086 A 19980724
 GB 1998-16921 A 19980805
 GB 1998-17097 A 19980807
 GB 1998-17200 A 19980808
 GB 1998-17632 A 19980814
 GB 1998-17943 A 19980819
 WO 1999-GB1779 W 19990604

AB There is considerable evidence that significant factor underlying the individual variability in response to disease, therapy and prognosis lies in a person's genetic make-up. There have been numerous examples relating that polymorphisms within a given gene can alter the functionality of the protein encoded by that gene thus leading to a variable physiol. response. In order to bring about the integration of genomics into medical practice and enable design and building of a technol. platform which will enable the everyday practice of mol. medicine a way must be invented for the DNA sequence data to be aligned with the identification of genes central to the induction, development, progression and outcome of disease or physiol. states of interest. According to the invention, the no. of genes and their configurations (mutations and polymorphisms) needed to be identified in order to provide crit. clin. information concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome. The identification of the identity of the core group of genes enables the invention of a design for genetic profiling technologies.

IT 106602-62-4, Amylin 148125-60-4

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(core group of disease-related genes; gene probes used for genetic profiling in healthcare screening and planning)

IT 158736-49-3, .beta.-Secretase

RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(.alpha. and .beta. and .gamma., core group of disease-related genes; gene probes used for genetic profiling in healthcare screening and planning)

=> sel hit rn

E1 THROUGH E13 ASSIGNED

=> file reg

FILE 'REGISTRY' ENTERED AT 14:53:28 ON 01 OCT 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 30 SEP 2002 HIGHEST RN 457600-76-9
 DICTIONARY FILE UPDATES: 30 SEP 2002 HIGHEST RN 457600-76-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
 PROPERTIES for more information. See STNote 27, Searching Properties
 in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s el-el3

```

1 106602-62-4/BI
  (106602-62-4/RN)
1 148125-60-4/BI
  (148125-60-4/RN)
1 158736-49-3/BI
  (158736-49-3/RN)
1 290828-24-9/BI
  (290828-24-9/RN)
1 290828-45-4/BI
  (290828-45-4/RN)
1 117871-30-4/BI
  (117871-30-4/RN)
1 126236-73-5/BI
  (126236-73-5/RN)
1 148784-57-0/BI
  (148784-57-0/RN)
1 154947-97-4/BI
  (154947-97-4/RN)
1 290828-30-7/BI
  (290828-30-7/RN)
1 290828-31-8/BI
  (290828-31-8/RN)
1 290828-62-5/BI
  (290828-62-5/RN)
1 290828-63-6/BI
  (290828-63-6/RN)
L23 13 (106602-62-4/BI OR 148125-60-4/BI OR 158736-49-3/BI OR 290828-24
      -9/BI OR 290828-45-4/BI OR 117871-30-4/BI OR 126236-73-5/BI OR
      148784-57-0/BI OR 154947-97-4/BI OR 290828-30-7/BI OR 290828-31-
      8/BI OR 290828-62-5/BI OR 290828-63-6/BI)

```

=> d ide can 123 1-13


L23 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2002 ACS
 RN 290828-63-6 REGISTRY
 CN D-Leucinamide, N-methyl-D-leucyl-D-valyl-D-phenylalanyl-2,3,4,5,6-

RUSSEL 09 / 781133

pentafluoro-D-phenylalanyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C36 H49 F5 N6 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:221242

L23 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2002 ACS
RN 290828-62-5 REGISTRY
CN D-Leucinamide, N-methyl-D-leucyl-D-valyl-D-phenylalanyl-4-fluoro-D-phenylalanyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C36 H53 F N6 O5
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:221242

L23 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2002 ACS

RN **290828-45-4** REGISTRY

CN D-Leucinamide, N-methyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 3: PN: WO0158470 PAGE: 27 claimed sequence

CN PPI 1019

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C36 H54 N6 O5

SR CA

LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 135:185457

REFERENCE 2: 133:221242

L23 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2002 ACS
 RN **290828-31-8** REGISTRY
 CN D-Leucinamide, N-propyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-
 (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C38 H58 N6 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:221242

L23 ANSWER 5 OF 13 REGISTRY COPYRIGHT 2002 ACS
 RN **290828-30-7** REGISTRY
 CN D-Leucinamide, N-ethyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-
 (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C37 H56 N6 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:221242


L23 ANSWER 6 OF 13 REGISTRY COPYRIGHT 2002 ACS
 RN 290828-24-9 REGISTRY
 CN D-Leucinamide, N,N-dimethyl-D-leucyl-D-valyl-D-phenylalanyl-D-phenylalanyl-
 (9CI) (CA INDEX NAME)

OTHER NAMES:

CN PPI 1007
 FS PROTEIN SEQUENCE; STEREOSEARCH
 MF C37 H56 N6 O5
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:185457

REFERENCE 2: 133:221242

L23 ANSWER 7 OF 13 REGISTRY COPYRIGHT 2002 ACS

RN 158736-49-3 REGISTRY
 CN .beta.-Secretase (9CI) (CA INDEX NAME)

OTHER NAMES:

CN .beta. Protein amyloidogenase
 CN .beta.-Amyloid protein precursor secretase
 CN .beta.-Site APP-cleaving enzyme
 CN .beta.-site APP-cleaving enzyme 1
 CN Amyloid precursor protein secretase
 CN APP secretase
 CN Aspartic protease BACE
 CN Aspartic protease BACE1
 CN D-Aspartyl-.beta.-amyloid secretase
 CN Memapsin 2
 CN Protease Asp2
 CN Proteinase BACE1
 MF Unspecified

CI MAN

SR CA

LC STN Files: ADISNEWS, BIOBUSINESS, BIOSIS, CA, CAPLUS, CEN, CIN, PROMT,
 TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

448 REFERENCES IN FILE CA (1962 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

453 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:199013
 REFERENCE 2: 137:197417
 REFERENCE 3: 137:194789
 REFERENCE 4: 137:183539
 REFERENCE 5: 137:180800
 REFERENCE 6: 137:163820
 REFERENCE 7: 137:163104
 REFERENCE 8: 137:150257
 REFERENCE 9: 137:136786
 REFERENCE 10: 137:134242

L23 ANSWER 8 OF 13 REGISTRY COPYRIGHT 2002 ACS

RN 154947-97-4 REGISTRY

CN Proteinase, amyloid precursor protein (human clone pRc/Zyme reduced) (9CI)
 (CA INDEX NAME)

OTHER NAMES:

CN 103: PN: WO0053776 FIG: 36 unclaimed protein
 CN 114: PN: WO0053776 FIG: 43 unclaimed protein
 CN 3: PN: WO0127257 SEQID: 3 unclaimed protein
 CN 66: PN: WO0053776 SEQID: 84 unclaimed protein
 CN GenBank AF013988-derived protein GI 2318115
 CN GenBank AF149289-derived protein GI 5791636
 CN GenBank AF243527-derived protein GI 11244764
 CN GenBank U62801-derived protein GI 1518788
 CN Kallikrein (human gene KLK6 isoenzyme hK6)
 CN Kallikrein hK6 (human gene KLK6)
 CN Kallikrein-like serine protease (human gene PRSS9)
 CN Neurosin (human clone pSPORT/SP59 precursor)
 CN Neurosin (human)
 CN Protease M (human precursor)
 CN Proteinase M (human gene KLK6)
 CN Proteinase M (human precursor)
 CN Proteinase M (human)
 CN Proteinase, amyloid precursor protein (human clone 56Z precursor)
 CN Proteinase, serine (human COLO 201 cell gene SP59 precursor)
 CN Zyme (human clone 56Z precursor)
 FS PROTEIN SEQUENCE
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
 12 REFERENCES IN FILE CA (1962 TO DATE)
 12 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:190398

REFERENCE 2: 135:56769
 REFERENCE 3: 135:29716
 REFERENCE 4: 134:309694
 REFERENCE 5: 133:248065
 REFERENCE 6: 132:233371
 REFERENCE 7: 128:241249
 REFERENCE 8: 127:344861
 REFERENCE 9: 127:77920
 REFERENCE 10: 126:101081

L23 ANSWER 9 OF 13 REGISTRY COPYRIGHT 2002 ACS
 RN 148784-57-0 REGISTRY
 CN DNA (human clone .lambda.h101 islet amyloid protein IAAP cDNA plus flanks)
 (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 MF Unspecified
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
 1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:190398

L23 ANSWER 10 OF 13 REGISTRY COPYRIGHT 2002 ACS
 RN 148125-60-4 REGISTRY
 CN Proteinase inhibitor, protease-nexin II (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN A4751 amyloid protein precursor
 CN Amyloid A4751 glycoproteins
 CN Amyloid A4751 proteins
 CN Glycoproteins, amyloid A4751
 CN Glycoproteins, amyloid A4751
 CN Plasminogen activator inhibitor PN 2
 CN Protease-nexin 2
 CN Protease-nexin II
 CN Proteins, ABPP 751
 CN Proteins, amyloid A4751
 CN Proteins, amyloid precursor protein 751
 CN Proteins, APP751
 CN Proteins, BPP751
 CN Proteins, protease-nexins, II
 CN Proteins, proteinase-nexins II
 MF Unspecified
 CI MAN
 SR CA

LC STN Files: BIOSIS, CA, CAPLUS, PROMT, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

102 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
102 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:121162

REFERENCE 2: 137:15809

REFERENCE 3: 136:398194

REFERENCE 4: 136:323313

REFERENCE 5: 136:132925

REFERENCE 6: 136:81953

REFERENCE 7: 136:4156

REFERENCE 8: 135:356303

REFERENCE 9: 135:342469

REFERENCE 10: 135:314399

L23 ANSWER 11 OF 13 REGISTRY COPYRIGHT 2002 ACS

RN 126236-73-5 REGISTRY

CN Glycophosphoprotein P (human clone pSVB1/pSVM113/pSVC6/pSVA4/pSVS13/pSVTH2
1 gene mdrl protein moiety reduced) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1: PN: WO0121762 SEQID: 1 unclaimed protein

CN 24: PN: WO0192877 SEQID: 2 unclaimed protein

CN 2: PN: WO9961589 SEQID: 2 unclaimed protein

CN GenBank M29447-derived protein GI 386862

CN P glycoprotein (human gene MDRL)

CN P glycoprotein (human)

FS PROTEIN SEQUENCE

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

6 REFERENCES IN FILE CA (1962 TO DATE)
6 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:34297

REFERENCE 2: 135:193985

REFERENCE 3: 135:190398

REFERENCE 4: 134:247227

REFERENCE 5: 132:9605

REFERENCE 6: 112:152804

L23 ANSWER 12 OF 13 REGISTRY COPYRIGHT 2002 ACS
 RN 117871-30-4 REGISTRY
 CN Amylin, prepro- (human clone .lambda.hIAP-1 reduced) (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 12: PN: WO9956763 SEQID: 12 unclaimed protein
 CN 2: PN: US6110707 SEQID: 53 claimed protein
 CN Amylin, prepro- (human clone .lambda.h201 reduced)
 CN GenBank X68830-derived protein GI 32583
 CN Islet amyloid polypeptide IAAP (human clone .lambda.h101)
 FS PROTEIN SEQUENCE
 DR 125199-66-8
 MF C436 H717 N125 O125 S3
 CI MAN
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
 10 REFERENCES IN FILE CA (1962 TO DATE)
 10 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:190398
 REFERENCE 2: 133:206891
 REFERENCE 3: 131:350243
 REFERENCE 4: 127:186606
 REFERENCE 5: 118:183631
 REFERENCE 6: 113:146480
 REFERENCE 7: 112:230555
 REFERENCE 8: 112:173362
 REFERENCE 9: 111:209451
 REFERENCE 10: 110:226301

L23 ANSWER 13 OF 13 REGISTRY COPYRIGHT 2002 ACS
 RN 106602-62-4 REGISTRY
 CN Amylin (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN Diabetes-associated peptide
 CN Insulinoma amyloid peptide
 CN Insulinoma amyloid polypeptide
 CN Islet amyloid polypeptide
 MF Unspecified
 CI COM, MAN
 SR CA
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
 CA, CANCERLIT, CAPLUS, CBNB, CEN, CHEMCATS, CIN, EMBASE, MEDLINE, MRCK*,
 PROMT, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

880 REFERENCES IN FILE CA (1962 TO DATE)

33 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

882 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:200265

REFERENCE 2: 137:190764

REFERENCE 3: 137:183587

REFERENCE 4: 137:179976

REFERENCE 5: 137:174934

REFERENCE 6: 137:174933

REFERENCE 7: 137:174932

REFERENCE 8: 137:174931

REFERENCE 9: 137:159362

REFERENCE 10: 137:150247